Spruce Biosciences, Inc.
TA-ERT
MPS IIIB
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on TA-ERT for MPS IIIB is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Our recent productive interactions with the FDA have provided clear next steps that strengthen our conviction in the development of TA-ERT for patients and families living with MPS IIIB, for which currently there are no approved therapies.”